Johnson & Johnson today announced the global launch of the Shockwave C2 Aero coronary intravascular lithotripsy (IVL) catheter.

Shockwave Medical's CMO discusses the C2 Aero launch, why the company is defining what qualifies as true IVL, and J&J's R&D ...

Shockwave Medical, Inc. SWAV, along with Genesis MedTech Group, received approval from China’s National Medical Products Administration for Intravascular Lithotripsy (“IVL”). The clearance paves the ...

Johnson & Johnson has officially launched its Shockwave C2 Aero Coronary IVL Catheter globally. Enhanced deliverability and repositioning capabilities target calcified coronary artery disease The ...

Shockwave C2+ Catheter Expands Utility of IVL in Calcified Coronary Arteries Shockwave C2+ is commercially available for the treatment of de novo coronary artery disease in Europe and select other ...

SANTA CLARA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...

Calcified femoropopliteal arterial disease remains a major challenge in endovascular therapy. Vessel preparation technologies have emerged to improve ...

SANTA CLARA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...

SANTA CLARA, CALIF., April 27, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified ...

Shockwave Medical, Inc. SWAV recently announced the full U.S. commercial availability of the Shockwave L6 Peripheral Intravascular Lithotripsy (IVL) Catheter. This follows the receipt of the FDA’s ...

LAS VEGAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, ...